eISSN: 1732-2707
ISSN: 1730-1270
HIV & AIDS Review. International Journal of HIV-Related Problems
Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
4/2020
vol. 19
 
Share:
Share:
more
 
 
Original paper

Association between selected immune markers and low ankle-brachial index in virologically suppressed HIV-infected patients on antiretroviral therapy in Nigeria

Chidozie Elochukwu Agu
1
,
Ikenna Kinsgley Uchendu
2
,
Chukwugozie Nwachukwu Okwuosa
2
,
Peter Uwadiegwu Achukwu
2

1.
Prime Health Response Initiative (PHRI)-sub-recipients of Global Fund HIV Impact Project, Ilorin, Kwara State, Nigeria
2.
Department of Medical Laboratory Science, Faculty of Health Science and Technology, College of Medicine, University of Nigeria Enugu Campus, Enugu State, Nigeria
HIV AIDS Rev 2020; 19, 4: 227-236
Online publish date: 2020/12/12
Article file
- HIV-00205-Agu.pdf  [0.29 MB]
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
 

Introduction

Since 2004, more than 30 low-income and middle-income countries (LMIC) worldwide have been receiving various human immunodeficiency virus (HIV) programs [1]. Through these programs, approximately 19.5 million people living with HIV (PLHIV) have obtained antiretroviral treatment (ART) [1, 2]. As more people comply with the uptake of anti­retroviral treatment in LMICs, there may be an improvement in the survival of PLHIV, which is currently observed in high-income countries [3]. On achieving the Joint United Nations Programme on HIV/AIDS (UNAIDS) ambitious 90–90–90 goals, acquired immune deficiency syndrome (AIDS)-related opportunistic diseases will drastically reduce [3], and non-communicable diseases may significantly become common [4, 5]. Furthermore, it was reported that HIV infection might increase the risk of non-communicable diseases (NCDs) due to activation of inflammatory markers and adverse events caused by certain antiretroviral drugs [4]. Elevated levels of immune activation markers and inflammation have been reported to predict an increased mortality and other adverse events in HIV infection [6].
Previously, the increased cardiovascular risk reported in HIV-patients was due to metabolic changes associated with ART as a result of the effect of viral protease inhibitors (PI) [7, 8]. The D:A:D study (data collection on adverse events of anti-HIV drugs) [8] showed a significant elevation in the incidence of acute myocardial infarction (AMI) after exposure to ART, with an elevated AMI risk of close to 30% after 6 years of treatment. HIV infection may enhance cardiovascular risk through different mechanisms, such as prolonged inflammation and immune activation, increased thrombotic activity, endothelial damage, indirect metabolic disorders, higher oxidative stress, and microbial translocation. There are several risk factors that may lead to peri­pheral artery disease in people living with HIV. These include the HIV infection itself, increased aging process in infected individuals, adverse effects of antiretroviral therapy, and increased occurrence of conventional cardiovascular risk factors, such as diabetes and dyslipidemia [9, 10]. Several other markers of immune activation (sCD163, sCD14, and CD14+/CD16+ monocyte expansion) on monocytes/macrophages are associated with HIV infection. These markers were reported to be elevated during HIV infection [11]. In addition, an elevation of some activated CD8 T lymphocytes human leukocyte antigen (HLA)-DR+CD38+ was observed [11, 12].
Although the relative risk of cardiovascular disease (CVD) is increased in patients with HIV, one limitation in studying CVD in this generally young patient population has been the relatively low absolute event rate in terms of CVD-related deaths [13]. As a result, several investigators have utilized cardiac imaging and ankle–brachial index (ABI) to document the burden of sub-clinical CVDs, better understand the underlying pathophysiological mechanisms, and follow the response to treatment interventions. The cardiac imaging measurements, however, are quite expensive and not readily available. Therefore, a suitable alternative is ABI, which is a simple, inexpensive, and non-invasive diagnostic test as a powerful indicator of systemic atherosclerosis and peripheral artery disease (PAD) and a strong predictor of mortality from cardiovascular causes in the general population [14, 15]. ABI is the screening tool for PAD. An ABI ≤ 0.9 (low ABI) is diagnostic of PAD [16]. The ABI between 0.91-0.99 (borderline values) is considered significant prognostic marker in higher cardiovascular mortality. The ABI ≥ 1.3 (high ABI) suggests rigidity and non-compressibility of lower limb arteries. Abnormal ABI values in asymptomatic patients are associated with a higher incidence of CVD [17]. This study aimed at determining associations between ankle-brachial index and selected immune markers among virologically suppressed HIV-infected patients on ART in Kwara State, Nigeria.

Material and methods

Study area

The study was conducted in Kwara, a state in western Nigeria, located within the North central geopolitical zone, commonly referred to as the Middle belt, with an estimated population of 2,365,353 inhabitants [18]. The primary ethnic group is Yoruba, with significant Nupe, Bariba, and Fulani minorities. Kwara state consists of 16 local government areas, including Asa, Baruten, Edu, Ekiti, Ifelodun, Ilorin East, Ilorin South, Ilorin West, Irepodun, Isin, Kaiama, Moro, Offa, OkeEro, Oyun, and Pategi. In Nigeria, HIV programs are largely funded by the President’s Emergency Plan for AIDS Relief (PEPFAR) and Global Fund, with a support from the Federal Ministry of Health and National Agency for Control of AIDS (NACA). The research ethical approval was obtained from the Kwara State Ministry of Health Ethical Committee (MOH/KS/EU/777/252). Enrollment into the study was voluntary and informed consent was obtained from all participants.

Study design

A cross-sectional study design was adopted for this study. Informed consent was obtained from all participants before their enrollment. Socio-demographic data were collected using a structured questionnaire after which, blood samples were obtained from the participants. The study participants include HIV-positive patients attending HIV clinic of the University of Ilorin Teaching Hospital (UITH) and Sabo Oke Medical Center, Ilorin, Kwara state, and the control group consisted of non-infected healthy participants resided within the same region. The study was conducted within six months, between July 2018 and December 2018.

Sample size determination

The sample size was calculated using the sample size for comparing two proportions [19]. n = (Zα/2+Zβ) 2 * (p1 (1-p1) +p2 (1-p2)) / (p1-p2)2, where Zα/2 is the critical value of the normal distribution at α/2 (e.g., for a confidence level of 95%, α is 0.05 and the critical value is 1.96), Zβ is the critical value of the normal distribution at β (e.g., for a power of 80%, β is 0.2 and the critical value is 0.84), and p1 and p2 are the expected sample proportions of the two investigated groups. However, considering that there are several cardiovascular risk factors with respective standard deviation in different studies, the sample size was not calculated using this formula. Literature review showed that a sample size of 144 participants was used in a similar study [20], with an extra 4% included to cater for non-responders. Thus, a total of 150 individuals living with HIV who have been on antiretroviral therapy (ART) for 6 months and above were recruited into the present study.

Subject selection

A total of 200 participants, 150 virologically suppressed (viral load < 1000 copies/ ml, WHO standard for low- and middle-income countries) HIV-infected participants on antiretroviral therapy (ART) and 50 uninfected controls within the age range of 18-50 years were investigated. The study lasted for 6 months, between July 2018 and December 2018. The study group participants were recruited using random sampling technique from the Sabo Oke Medical Center Ilorin of ART treatment and care unit, and the University of Ilorin Teaching Hospital (UITH) supported by PEPFAR (President’s Emergency Plan for AIDS Relief).

Inclusion criteria

HIV-infected individuals between 18-50 years presently on ART for at least six months, with viral RNA of < 1000 copies/ml.

Exclusion criteria

HIV-infected adults who defaulted from ART use, with a known coronary heart disease or diabetes mellitus, patients on statins for at least 6 months, and those with known co-infections, such as tuberculosis and hepatitis B and C.

Data collection tools

A detailed questionnaire interview was conducted to obtain personal data on each participant enrolled into the study, including demographic characteristics and family history of cardiovascular diseases based on the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) criteria [21], past and current medication usage, presence of co-infections, and HIV disease characteristics (duration of HIV infection, duration of ART treatment, viral RNA count, nadir and current CD4+ T cell count, and past and current ART regimen). Medical history along with physical examination, with height, weight, waist, and hip measurements, and brachial and ankle blood pressure obtained from all the participants enrolled in the study.

Ankle-brachial index measurements

The ankle-brachial index (ABI) was determined using a hand-held continuous wave doppler device 8 MHz probe, as described by Kwiatkowska et al. [14] and Olalla et al. [22]. The examination was performed after 5 minutes of rest in the supine position. A pressure cuff, which was placed on either arm, and subsequently above the ankles was used. The probe was placed at the cubital fossa, medial malleolus, and dorsal foot for systolic blood pressure detection at the brachial artery, left posterior tibial, and dorsalis pedis artery, respectively. The cuff was inflated to 20 mm above the audible pulse signal and then slowly emptied, until the first pulse signal was detected. Ankle-brachial index value was determined by taking the higher pressure of two arteries at the ankles divided by the highest brachial systolic blood pressures. Using the formula below, ABI was calculated as: ABI = highest systolic blood pressure in the ankles highest systolic blood pressure in both arms Interpretation of ankle-brachial index measurements: normal ABI = 1.0-1.4, borderline ABI = 0.91-0.99, PAD ≤ 0.9.

Anthropometric measurements

Anthropometric parameters, such as height (m), weight (kg), waist circumference (cm), and hip circumference (cm) were determined. Weight and height were measured with the subjects wearing light clothing and without shoes. Weight was measured in kilogram using a balanced scale, while height was measured in meters using a wall-mounted ruler with the subjects standing with feet together, and with head, shoulder, buttocks, and heels touching the wall. Waist and hip circumferences were measured to the nearest 0.1 cm using a flexible but inelastic measuring tape. Moreover, waist circumference was taken between the costal margin and the iliac crest in the mid-auxiliary line around the gluteal region [23]. Body mass index (BMI) was calculated as weight in kilogram divided by the square of the height in meters (kg/m2), waist-to-hip (WHR) was determined by dividing the measurement of the waist (cm) by that of the hip (cm), and then used together with the waist circumference as an index of central obesity. The following definitions were used: general obesity a BMI of ≥ 30 kg/m2, central obesity – a waist circumference of ≥ 80 cm in women or ≥ 94 cm in men, waist-to-hip ratio of ≥ 0.90 in men or ≥ 0.85 in women. Normal weight was defined as BMI value of 18.5-24.9 kg/m2 [21].

Sample collection

Ten milliliters (10 ml) of blood was obtained from the ante-cubital vein by venipuncture after at least a 12-hour overnight fast, and was dispensed into a plain container, allowed to clot at room temperature, spun at 5,000 r.p.m. for 5 minutes; the serum was separated and cryopreserved for analysis of immunologic markers.

Biochemical analysis

Interleukin-6 and sCD14 were determined using enzyme-linked immunosorbent assay (ELISA) [24]. The kit was obtained from Melsin Medical Co., Limited (Kuacheng District, Jilin Province, China).

Statistical analysis

The generated data was analyzed using Microsoft excel, statistical package for social science (SPSS version 20.0, California Inc., USA) and GraphPad prism (GraphPad Software, Inc., California, USA). Data was expressed as mean ± standard deviation, and data among groups was compared using one-way analysis of variance (ANOVA), followed by post-hoc analysis with Tukey’s test. Correlation analysis was performed using Pearson’s correlation, which was used to determine inter-variable association between various selected parameters. Values of p < 0.05 were considered statistically significant.

Results

The study participants were further divided into 3 groups based on duration on ART (1-5, 6-9, and ≥ 10 years), ART drug regimen (AZT/ 3TC/ NVP, TDF/ 3TC/ EFV, and LPV/r), and ankle-brachial index measurements (normal ABI, 1-1.3; borderline ABI, 0.9-0.99; and low ABI, < 0.9). Table 1 demonstrates the sociodemographic characteri­stics, and anthropometric and clinical parameters of the HIV-infected study group. Of the 150 virologically suppressed HIV-infected study participants recruited into the study, 109 (72.7%) were females and 41 (27.3%) were males, with a mean age of 43.73 ± 8.74 years. Furthermore, 120 (80.0%) of the study participants were Yorubas, 10 (6.7%) Ibos, 4 (2.7%) Hausas, while 16 (10.7%) were from other ethnic groups. 94 (62.7%) were Christians, 55 (36.7%) were Muslims, and 1 (0.7%) was of other religion. The study participants level of education revealed that 11 (7.3%) had no formal education, 33 (22.0%) had primary education, 44 (29.3%) had secondary education, and 62 (41.3%) had tertiary education. Anthropometric results of the study group revealed a mean body mass index (BMI) of 25.43 ± 5.46. Based on their BMI value, 78 (52%) of the study participants had normal weight, 38 (25.3%) were overweight, and 34 (22.7%) were obese. The study participants recorded mean systolic blood pressure (SBP) of 121.67 ± 20.96, diastolic blood pressure (DBP) of 81.47 ± 7.98 as well as mean of 7.73 ± 3.52 years of HIV infection, 7.47 ± 3.42 years on ART, mean nadir/ baseline CD4+ T cell count of 263.18 ± 229.58 cells/mm3, mean current CD4+ T cell count of 505.42 ± 265.85 cells/mm3, and mean HIV viral RNA count of 40.95 ± 111.61 copies/ml. With regards to drug regimen, 93 (61.6%) of the study participants were on the first-line fixed-dose regimen, with zidovudine/lamivudine/nevirapine (AZT/3TC/NVP), 46 (30.5%) were on tenofovir/lamivudine/efavirenz (TDF/3TC/EFV), while 11 (7.3%) were on protease inhibitor with lopinavir/ritonavir (LPV/r). Based on traditional cardiovascular risk factors evaluated, the study group recorded a prevalence rate of 13 (8.6%) for family history of cardiovascular disease, 6 (4.0%) for type 2 diabetes mellitus, 24 (15.9%) for hypertension, 26 (17.3%) for metabolic syndrome based on the IDF (the International Diabetes Association) criteria [25], 1 (0.7%) for smoking, and 23 (15.2%) were on lipid lowering drugs.
Table 2 presents the comparison of cardiovascular risk factors, and anthropometric and ankle-brachial index of the study and control groups, using Student’s t-test and c2 analy­ses. The results revealed that diastolic blood pressure was significantly higher in the study group compared to the control group (p < 0.05). The control group recorded significantly higher mean levels of ankle-brachial index, WC, WHR, and BMI compared to the study group (p < 0.05). Based on the ankle-brachial index category, the study group recorded a higher prevalence of low ABI: 22 (14.6%) compared to the control group 3 (2%); normal ABI of 42 (27.8%) compared to 16 (10.6%) recorded in the control group and borderline ABI of 86 (57%) compared to 31 (20.5) recorded in the control group. No significant association was observed between the study and control groups based on the size of the specific sub-group, according to ABI categories (p > 0.05). With regards to the presence of cardiovascular risk factors, the study group recorded a higher prevalence rate of 26 (17.3%) and 6 (4%) for metabolic syndrome and diabetes mellitus compared to 5 (10%) for metabolic syndrome and 1 (2%) for diabetes mellitus recorded by the controls. No significant association was observed between the study and control groups based on the presence of metabolic syndrome and diabetes mellitus (p > 0.05). A significant association was observed in the prevalence of family history of CVD between the study 13 (8.6%) and control groups 20 (13.2%), p < 0.05, with higher prevalence rate recorded by the control group.
Comparison of anthropometric and clinical parameters based on the duration on ART in the study group are depicted in Table 3. Age, ankle-brachial index, and current CD4+ T cell count significantly varied among the groups (p < 0.05). No significant difference was observed in BMI, WC, WHR, SBP, and DBP among the three groups (p > 0.05). Table 4 shows the comparison of anthropometric parameters and clinical data of the study group based on ART regimen. WHR was significantly higher in study participants on AZT/3TC/NVP compared to those on LPV/r (p < 0.05), while ABI showed no significant difference between the two groups (p > 0.05). No significant difference was also observed in WHR and ABI in study participants on TDF/3TC/EFV regimen compared to those on LPV/r regimen (p > 0.05). Comparison of anthropometric parameters and clinical data based on ankle-brachial index measurements in the study group, stratified into 3 groups (normal ABI = 1-1.3, borderline ABI = 0.9-0.99, and low ABI = < 0.9) are described in Table 5. No significant difference was observed in age, BMI, WC, WHR, nadir and current CD4+ T cell count, duration on ART, interleukin (IL)-6, and sCD14 among the 3 groups (p > 0.05).
Table 6 shows logistic regression analysis of risk factors associated with low ABI value in the study group. Low ABI presented associations with CD4 T cell < 200 copies/ml (OR 2.635, p = 0.250), WHR (OR 928.39, p = 0.250), hypertension (OR 2.115, p = 0.335), and detectable viraemia ≥ 20 copies/ml (OR 1.375, p = 0.511). No significant association or odd ration > 1 was observed for age, BMI, CVD family history, diabetes mellitus, protease inhibitors, and low ABI in the study group (OD ≤ 1, p > 0.05).

Discussion

Even after a successful treatment, high-risk for cardiovascular morbidity and mortality is still a problem in HIV-infected patients due to the effects of HIV and/or ART [14, 26]. This study determined the prevalence of peripheral artery disease (PAD) in people living with HIV using ankle-brachial index measurements, and also examined inflammation and immune activation as possible predictors of PAD in the study group. The study population was relatively young and mainly composed of female participants. Moreover, the study group consisted of relatively healthy HIV-infected participants, and reflected in 22.7% obesity rate compared with 32% reported, using the 2003-2004 NHANES (National Health and Nutrition Examination Survey) data, for the general population [27].
PAD disease has been shown to be associated with future cardiovascular events particularly ischemic strokes and myocardial infarction [28]. Ankle-brachial index is considered an effective screening tool with a low ABI of < 0.9 is suggestive of PAD. A study conducted by Gutierrez [29] among HIV-infected patients revealed an association between low ABI and high carotid intima media thickness, indicating that in HIV-infected patients, low ABI may be a surrogate marker for sub-clinical atherosclerosis. In this present study, the ankle-brachial index was significantly lower in the HIV-infected group compared to the HIV-negative control group, with 14.6% compared to 2% prevalence rate observed in the control group. This is consistent with Periard et al. [30], who reported a high prevalence rate (20.7%) of PAD among HIV patients on ART in a Swiss cohort. Findings from this study are also in line with the research of Beckman et al. [31], who reported a 19% increased risk of PAD compared to non-HIV-infected veterans.
Findings from this study revealed a significantly higher mean value of IL-6 in HIV-infected study group compared to the uninfected control group. This finding is consistent with results from other studies. In SMART study, the levels of high sensitivity C-reactive protein (hsCRP) and IL-6 in HIV-infected individuals with a suppressed viral load were approximately 50% higher than matched controls from general population (from the multi-ethnic study of atherosclerosis [MESA] and the coronary artery risk development in young adults [CARDIA] studies) [32]. IL-6 is strongly associated with atherogenesis and pathogenesis of CVD. It can stimulate hepatic synthesis of acute-phase proteins, activate endothelial cells, promote lymphocyte proliferation, neutrophil migration, and macrophage differentiation [33, 34]. However, in this present study, no association was observed between IL-6 and low ABI. This is in contrast with reports from other studies examining the associations of IL-6 and markers of sub-clinical atherosclerosis, such as carotid intima media thickness (IMT) measurements. Longenecker et al. [35] found that IL-6 was positively associated with common CIMT in a study of 60 HIV-infected study patients with an HIV-1 RNA less than 400 copies/ml, but the association was no longer statistically significant after an adjustment for traditional cardiovascular risk factors. Recently,
Siedner et al. [36] observed an association between plasma IL-6 levels at 6 months after ART initiation and common CIMT. However, the results of this study were consistent with reports of Mangili et al. [37], who reported no significant trend towards higher circulating levels of IL-6 in patients with sub-clinical atherosclerosis measured with CIMT. These findings may be secondary to the full suppression of HIV viremia in our cohort, as previous studies have demonstrated an association between inflammatory biomarkers and HIV RNA levels [38].
In this study, the mean levels of sCD14 was significantly elevated in HIV-infected study group compared to the uninfected control group. This agrees with the study of Fitch et al., who demonstrated significantly higher mean values of immune activation markers (sCD163 and sCD14) in a group of HIV-infected women compared to uninfected controls. CD14 is a coreceptor on innate immune cells that, together with Toll-like receptor-4 and lipopolysaccharide (LPS)-binding protein, allows these cells to scavenge circulating bacterial LPS and releases nuclear factor Κb-dependent inflammatory cytokines [39]. The soluble form of CD14 (sCD14) is shed by activated monocytes and has been proposed as a surrogate marker of LPS-induced activation [40]; although, the liver also produces sCD14 as an acute phase protein in response to IL-6. Plasma sCD14 and LPS are elevated in chronic HIV infection and are associated with poor immunologic response to ART, progression of HIV-1 and HIV-2 disease, and mortality [40]. In the general population, plasma sCD14 levels have recently been independently associated with myocardial infarction, coronary heart disease (CHD), and all-cause mortality among older (> 65 years) men and women in a cardiovascular health study (CHS) [41]. In contrast, soluble CD14 was not associated with sub-clinical vascular disease as evaluated using ABI and did not predict low ABI in the study group, which are in contrasts with previous study by Longenecker et al. [35], who observed an independent association between sCD14 with coronary artery calcification, sCD14 predicted the extent of sub-clinical disease in other vascular beds in a group of HIV-infected cohort. The lack of association observed in this study could be due to the cross-sectional study design used, as these reports were observed in prospective follow-up studies. Also, this study included a relatively young population (average age, 44 years), in which atherosclerotic vascular changes and burden were expected to be low. However, this study reports are consistent with the results of Fitch et al. [42], who demonstrated significantly higher mean values of immune activation markers (sCD163 and sCD14) in a group of HIV-infected women compared to uninfected controls.
This current study has a number of limitations as well as strengths. To our knowledge, this is the first study to investigate PAD specifically in virologically suppressed HIV- infected individuals in our population, and to relate indices of inflammation, immune activation, and traditional CVD risk factors to such PAD. Though, because this study is cross-sectional, definitive conclusions on causality cannot be made, and further longitudinal studies relating changes in inflammation, immune activation, and CVD risk factors for low ABI characteristics in HIV-infected individuals may be necessary.

Conclusions

The levels of IL-6 and sCD14 were significantly higher in the study group compared to the uninfected controls despite viral suppression, but showed no association with low ABI. The relationship between low ABI with markers of inflammation and immune activation deserves additional investigations. These results suggest that patients living with HIV on effective ART, despite achieving viral suppression, could be at a risk of developing sub-clinical CVD compared to uninfected individuals.

Acknowledgments

We would like to thank our study participants for spending their time with us during data collection period. Second, we would like to thank families, friends, and organization, who helped us a lot during the study period. Additionally, we would like to express our special gratitude to the management and staff of HIV clinic at the University of Ilorin Teaching Hospital (UITH) and the Sabo Oke Medical Center, Ilorin, Kwara state, Nigeria.

Conflict of interest

The authors declare no conflict of interest with respect to the research, authorship, and/or publication of this article.
1. Health Organization. The global burden of disease: 2004 update 2009. Available at: http://www.who.int/healthinfo/global_burden_disease/2004_report (Accessed: 22.07.2018).
2. Debussche X, Balcou-Debussche M, Baranderaka NA, et al. Community health education network for the preve World ntion of cardiovascular disease and diabetes in Burundi: development and first results. Glob Health Promot 2010; 17 (2 Suppl): 68-75.
3. Hofman K, Ryce A, Prudhomme W, et al. Reporting of non-communicable disease research in low- and middle-income countries: a pilot bibliometric analysis. J Med Libr Assoc 2006; 94: 415-420.
4. Holmes MD, Dalal S, Volmink J, et al. Non-communicable diseases in sub-Saharan Africa: the case for cohort studies. PLoS Med 2010; 7: e1000244.
5. World Health Organization. Global status report on noncommunicable diseases 2010/2011. Available at: http://www.who.int/nmh/publications/ncd_report2010 (Accessed: 22.07.2020).
6. El-Sadr WM, Lundgren J, Neaton JD, et al.; Strategies for Management of Antiretroviral Therapy (SMART) Study Group. CD4+ count guided interruption of antiretroviral treatment. N Engl J Med 2006; 355: 2283-2296.
7. Gallet B, Pulik M, Genet P, et al. Vascular complications associated with use of HIV protease inhibitors. Lancet 1998; 351: 1958-1959.
8. Friis-Møller N, Sabin CA, Weber R, et al.; Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination of antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349: 1993-2003.
9. Grunfeld C, Delaney JA, Wanke C, et al. Preclinical atherosclerosis due to HIV infection: carotid intima-media thickness measurements from the FRAM study. AIDS 2009; 23: 1841-1849.
10. Capeau J, Caron M, Vigouroux C. Les lipodystrophies secondaires auxtraitements antirétroviraux de l’infection par le VIH [Lipodystrophy secondary to antiretroviral therapy for HIV infection]. Med Sci (Paris) 2006; 22: 531-536.
11. Sandler NG, Sereti I. Can early therapy reduce inflammation? Curr Opin HIV/AIDS 2014; 9: 72-79.
12. Liovat AS, Rey-Cuillé MA, Lécuroux C. Acute plasma biomarkers of T cell activation set-point levels and of disease progression in HIV-1 infection. PLoS One 2012; 7: e46143.
13. Ingle SM, May MT, Gill MJ, et al. Impact of risk factors for specific causes of death in the first and subsequent years of antiretroviral therapy among HIV-infected patients. Clin Infect Dis 2014; 594: 287-297.
14. Kwiatkowska W, Knysz B, Arczynska K, et al. Peripheral arterial disease and ankle-brachial index abnormalites in young and middle-aged HIV-positive patients in Lower Silesia, Poland. PLoS One 2014; 12: 1-18.
15. Hooi JD, Kester AD, Stoffers HE, et al. Asymptomatic peripheral arterial occlusive disease predicted cardiovascular morbidity and mortality in a 7-year follow- up study. J Clin Epidemiol 2004; 57: 294-300.
16. Norgren L, Hiatt WR, Dormandy JA, et al.; TASC II Working Group. Inter-society consensus for the management of peripheral artery disease (TASC II). J Vasc Surg 2007; 45 (Suppl S): S5-67.
17. Aboyans V, Criqui MH, McClelland RL, et al. Intrinsic contribution of gender and ethnicity to normal ankle–brachial index values: The Multi-Ethnic Study of Atherosclerosis (MESA). J Vasc Surg 2007; 45: 319-327.
18. National Population Commission, 2006. ‘Enumerators manual’, March. Third Report of the Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult
19. Treatment Panel III). The guidelines 2004. National Heart Lung and Blood Institute. Available at: http://www.nhlbi.nih.gov/guidelines/cholesterol/index.html (Accessed: 3.08.2018).
20. Wang H, Chow SC. Sample Size Calculation for Comparing Proportions. Wiley Encyclopedia of Clinical Trials; 2007.
21. Félicité K, Yacouba M, Ba H, et al. Prevalence and risk factors of peripheral artery disease in black Africans with HIV infection: a cross-sectional hospital-based study. Vasc Health Risk Manag 2018; 14: 401-408.
22. Lipsy RJ. The National Cholesterol Education Program Adult Treatment Panel III guidelines. J Manag Care Pharm 2003; 9 (1 Suppl): 2-5.
23. Olalla J, Salas D, Del Arco A, et al. Ankle-branch index and HIV: the role of antiretrovirals. HIV Med 2009; 10: 1-5.
24. Agu C, Usoro C, Inaku K, et al. Cross-sectional analysis of cardiovascular risk markers among obese males and females in Southern Nigeria. Scholars Journal of Applied Medical Sciences 2016; 4 (5A): 1471-1478.
25. Uotila M, Ruoslaliti E, Engvall E. Two-site sandwich enzyme immunoassay with monoclonal antibody to human alpha-fetoprotein. J Immunol Methods 1981; 42: 11-15.
26. Alberti K, Zimmet P, Shaw J. Metabolic syndrome: a new world‐wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 2006; 23: 469-480.
27. McDermott MM, Liu K, Criqui MH, et al. Ankle-brachial index and subclinical cardiac and carotid disease: the multiethnic study of atherosclerosis. Am J Epidemiol 2005; 162: 33-41.
28. Katherine S, Handan W, Matthew L. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria. Diabetes Care 2007; 30: 113-119.
29. Poredos P, Jug B. The prevalence of peripheral arterial disease in high risk subjects and coronary or cerebrovascular patients. Angiology 2007; 58: 309-315.
30. Gutierrez F, Enrique B, Sergio P, et al. Relationship between ankle–brachial index and carotid intima-media thickness in HIV-infected patients. AIDS 2008; 22: 1369-1376.
31. Periard D, Cavassini M, Taffe P, et al. High prevalence of peripheral arterial disease in HIV-infected persons. Clin Infect Dis 2008; 46: 761-767.
32. Beckman J, Duncan M, Alcorn C, et al. Association of human immunodeficiency virus infection and risk of peripheral artery disease. Circulation 2018; 138: 255-265.
33. Neuhaus J, Jacobs DR, Baker JV, et al. Markers of inflammation, coagulation, and renal function in HIV-infected adults in SMART and in two large population-based cohorts. J Infect Dis 2010; 201: 1788-1795.
34. Hunter CA, Jones SA. IL-6 as a keystone cytokine in health and disease. Nat Immunol 2015; 16: 448-457.
35. Hartman J, Frishman WH. Inflammation and atherosclerosis: a review of the role of interleukin-6 in the development of atherosclerosis and the potential for targeted drug therapy. Cardiol Rev 2014; 22: 147-151.
36. Longenecker CT, Funderburg NT, Jiang Y, et al. Markers of inflammation and CD8 T-cell activation, but not monocyte activation, are associated with subclinical carotid artery disease in HIV-infected individuals. HIV Med 2013; 14: 385-390.
37. Siedner MJ, Kim JH, Nakku RS, et al. Persistent immune activation and carotid atherosclerosis in HIV-infected ugandans receiving anti­retroviral therapy. J Infect Dis 2016; 213: 370-378.
38. Mangili A, Polak JF, Quach LA, et al. Markers of atherosclerosis and inflammation and mortality in patients with HIV infection. Athero­sclerosis 2011; 214: 468-473.
39. Kuller LH, Tracey R, Belloso W, et al. Activation of inflammatory and coagulation pathways is associated with mortality in patients with HIV infection. PLoS Med 2008; 5: e203.
40. Arroyo-Espliguero R, Avanzas P, Jeffery S, et al. CD14 and toll-
41. like receptor 4: a link between infection and acute coronary events?
42. Heart 2004; 90: 983-988.
43. Lederman MM, Smeaton L, Smith KY, et al. Cyclosporin A provides no sustained immunologic benefit to persons with chronic HIV-1 infection starting suppressive antiretroviral therapy: results of randomized, controlled trial of the AIDS Clinical Trials Group.
44. J Infect Dis 2006; 194: 1677-1685.
45. Lederman MM, Calabrese L, Funderburg NT, et al. Immunologic failure despite suppressive antiretroviral therapy is related to activation and turnover of memory CD4 cells. J Infect Dis 2011; 204: 1217-1226.
46. Fitch KV, Srinivasa S, Abbara S, et al. Noncalcified coronary atherosclerotic plaque and immune activation in HIV-infected women. J Infect Dis 2013; 208: 1737-1746.
Copyright: © 2020 Polish AIDS Society. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Quick links
© 2021 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe